All News AstraZeneca PLC

Equities

AZN

GB0009895292

Real-time Estimate Cboe Europe Other stock markets 05:35:02 2024-06-03 am EDT			5-day change	1st Jan Change
12,157 ^GBX	-0.27%		+1.30%	+14.94%

11:19am	AstraZeneca's Tagrisso Reduces Lung Cancer Progression in Phase 3 Trial	MT
10:35am	AstraZeneca: Tagrisso shows promise in lung cancer	CF

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AstraZeneca's Tagrisso Reduces Lung Cancer Progression in Phase 3 Trial	05:19am	MT
AstraZeneca: Tagrisso shows promise in lung cancer	04:35am	CF
AstraZeneca Says Imfinzi Reduced Risk of Death for Small-Cell Lung Cancer Patients	04:35am	MT
AstraZeneca: conclusive trial in lung cancer	04:22am	CF
AstraZeneca cancer treatment Tagrisso recommended for approval in EU	04:00am	AN
AstraZeneca: conclusive trial for Enhertu in breast cancer	03:58am	CF
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38%	03:54am	MT
AstraZeneca's Tagrisso Secures Recommendation for EU Approval for Advanced Lung Cancer with Chemotherapy	02:32am	MT
AstraZeneca's Imfinzi Lowers Risk of Death in Patients with Limited-stage Small Cell Lung Cancer	12:42am	MT
AstraZeneca Reports Positive Results from Non-small Cell Lung Cancer Drug Trial	12:39am	MT
AstraZeneca Reports Positive Results for Metastatic Breast Cancer Drug	12:28am	MT
Japan System Techniques Partners City of Takamatsu, AstraZeneca on Education Programs on COPD	11:43pm	MT
Astra's Enhertu breast cancer trial shows 'unprecedented' results	Jun. 02	RE
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial	Jun. 02	BU
AstraZeneca : Tagrisso reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial	Jun. 02	PU
Astra's Enhertu delays breast cancer in patients with low HER2 levels	Jun. 02	RE
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo	Jun. 02	BU
Astrazeneca Safety Profile Of Enhertu Was Consistent With Previous Breast Cancer Clinical Trials With No New Safety Concerns Identified	Jun. 02	RE
ASTRAZENECA: SAFETY PROFILE OF ENHERTU WAS CONSISTENT WITH PREV…	Jun. 02	RE
ASTRAZENECA: DATA FROM TRIALS IN HER2-POSITIVE METASTATIC BREAS…	Jun. 02	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT